Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
Study of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAM1906
U.S. Govt. ID: NCT02066532
Contact: Kevin Kalinsky, MD, MS: 212-305-1945 / kk2693@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether the combination of study drugs Ruxolitinib plusTrastuzumab is safe and effective in stopping breast tumor growth in patients with HER2 positivemetastatic breast tumors who have already received Trastuzumab. Trastuzumab (Herceptin) is an FDA-approved treatment for HER2 positive breast cancer.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Do you have locally recurrent or metastatic breast cancer? Yes No
Have you had prior therapy with pertuzumab and ado-trastuzumab? Yes No
Are you able to swallow, retain, and absorb medication by mouth? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kevin Kalinsky, MD, MS
kk2693@cumc.columbia.edu
212-305-1945
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE